Search

Displaying results 4191 - 4200 of 4822 in total
  1. Drug

    Trabedersen

    go.drugbank.com/drugs/DB05697
    Investigational

  2. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  3. Drug

    Betaprodine

    go.drugbank.com/drugs/DB01473
    ExperimentalIllicit

    It has been used in obstetrics, as pre-operative medication, for minor surgical procedures, and for dental procedures. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1067)

  4. Drug

    Maropitant

    go.drugbank.com/drugs/DB11427
    ExperimentalVet approved

    It was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats.

  5. Drug

    VPM4001

    go.drugbank.com/drugs/DB05089
    Experimental

    It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ).

  6. Drug

    CYT-6091

    go.drugbank.com/drugs/DB05991
    Experimental

    It was under investagtion in clinical trials NCT00356980 and NCT00436410 for the treatment of various cancers.

  7. Drug

    TB-402

    go.drugbank.com/drugs/DB06050
    Investigational

    It is expected to be developed as a potential treatment to prevent blood clot formation in connection with certain types of heart arrhythmia, such as atrial fibrillation.

  8. Drug

    Bisegliptin

    go.drugbank.com/drugs/DB06127
    Investigational

    It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion

  9. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase

  10. Drug

    2-Methoxyestradiol

    go.drugbank.com/drugs/DB02342
    Investigational

    It has undergone Phase 1 clinical trials against breast cancers and preclinical studies suggest that 2ME2 could also be effective against inflammatory diseases such as rheumatoid arthritis.